Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26355
Title: Characteristics of people on long-acting injectable antipsychotics in Australia: Data from the 2010 National Survey of High Impact Psychosis.
Austin Authors: Suetani, Shuichi;Siskind, Dan;Phillipou, Andrea ;Waterreus, Anna;Morgan, Vera A;Castle, David
Affiliation: Department of Psychiatry, University of Toronto, Toronto, Canada
St Vincent's Health Australia, Melbourne, VIC, Australia
School of Medicine, Griffith University, Nathan, QLD, Australia
Metro South Addiction and Mental Health Services, Woolloongabba, QLD, Australia
The University of Queensland, Brisbane, QLD, Australia
Physical and Mental Health Stream, Queensland Centre for Mental Health Research, Brisbane, QLD, Australia
Swinburne University of Technology, Melbourne, VIC, Australia
Centre for Clinical Research in Neuropsychiatry, Division of Psychiatry, The University of Western Australia, Perth, WA, Australia
The University of Melbourne, Melbourne, VIC, Australia
Neuropsychiatric Epidemiology Research Unit, School of Population and Global Health, The University of Western Australia, Perth, WA, Australia
Centre for Complex Interventions, Centre for Addictions and Mental Health, Toronto Canada
Austin Health
Issue Date: 27-Apr-2021
Date: 2021-04-27
Publication information: The Australian and New Zealand journal of psychiatry 2021; online first: 27 April
Abstract: This study investigates (1) the proportion of people with psychosis who are on long-acting injectable antipsychotics; (2) the difference in the demographic, clinical, substance use and adverse drug reaction profiles of people taking long-acting injectables compared to oral antipsychotics; and (3) the differences in the same profiles of those on first-generation antipsychotic versus second-generation antipsychotic long-acting injectables. Data were collected as part of the Survey of High Impact Psychosis. For this study, participants with diagnoses of schizophrenia or schizoaffective disorder who were on any antipsychotic medication were included (Nā€‰=ā€‰1049). Nearly a third (31.5%) of people with psychosis were on long-acting injectables, of whom 49.7% were on first-generation antipsychotic long-acting injectables and 47.9% were on second-generation antipsychotic long-acting injectables. This contrasts with oral antipsychotics where there was a higher utilisation of second-generation antipsychotics (86.3%). Of note, compared to those on the oral formulation, people on long-acting injectables were almost four times more likely to be under a community treatment order. Furthermore, people on long-acting injectables were more likely to have a longer duration of illness, reduced degree of insight, increased cognitive impairment as well as poor personal and social functioning. They also reported more adverse drug reactions. Compared to those on first-generation antipsychotic long-acting injectables, people on SGA long-acting injectables were younger and had had a shorter duration of illness. They were also more likely to experience dizziness and increased weight, but less likely to experience muscle stiffness or tenseness. Long-acting injectable use in Australia is associated with higher rates of community treatment order use, as well as poorer insight, personal and social performance, and greater cognitive impairment. While long-acting injectables may have the potential to improve the prognosis of people with psychosis, a better understanding of the choices behind the utilisation of long-acting injectable treatment in Australia is urgently needed.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26355
DOI: 10.1177/00048674211009602
ORCID: 0000-0002-2487-5691
0000-0002-2072-9216
0000-0002-1648-7701
0000-0003-3600-9042
Journal: The Australian and New Zealand journal of psychiatry
PubMed URL: 33906481
Type: Journal Article
Subjects: Long-acting injectable antipsychotics
metabolic
psychosis
schizophrenia
substance use
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Oct 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.